Reber Genetics Co.

What Reber Genetics Co. does

Reber Genetics Co., Ltd. is a Taiwanese animal vaccine company that develops, manufactures, and commercializes targeted subunit vaccines primarily for the swine industry, with the stated innovation of applying human cancer immunotherapy principles to animal disease treatment. Founded in 2008 and listed on Taiwan's GreTai Securities Market in November 2014 (stock code 6479), the company operates a PIC/S GMP-certified manufacturing plant in Taoyuan (Guanyin District) with a stated maximum annual capacity of 100 million doses — the first such facility for animal vaccines in Taiwan.

The company's core technology is a proprietary targeted subunit vaccine platform that combines reverse genetic engineering for antigenic epitope selection with a Pseudomonas exotoxin A-based antigen delivery system. This system uses detoxified PE fused with target pathogen antigens and KDEL endoplasmic reticulum retention signals to drive antigens through the MHC-I pathway, activating cytotoxic T cell responses alongside humoral immunity. Its commercialized product portfolio comprises PRRSFREE/PRRSQ (the world's first PRRS subunit vaccine, launched in Taiwan in April 2012), CIRCOQ (a PCV2 subunit vaccine launched in 2019), and PEDQ (the world's first and only PED subunit vaccine, launched in December 2024), with pending registrations for HCFREE (Classical Swine Fever E2) and PCCOM (combined PCV2+PRRS). Patents on the core platform have been granted in the US, Europe, China, South Korea, and Canada.

Reber employs a multi-channel go-to-market model: a direct sales force serves large commercial pig farms in Taiwan, while international markets (Russia, Philippines, Vietnam, Thailand, South Korea, Malaysia, and Japan-adjacent via Meiji Animal Health) are served through exclusive distributor partnerships. Revenue streams include proprietary vaccine product sales, distribution agency fees for foreign products, ODM/OEM contract manufacturing, and technology licensing. Within three years of launch, PRRSFREE captured over 55% market share in Taiwan's PRRS vaccine market, displacing Boehringer Ingelheim. Forward strategy includes companion animal cancer immunotherapy (canine pilot with NTU), poultry vaccines, and silkworm-cell-based recombinant protein production via a 2025 partnership with Japan's Kaico Co.

Name

Reber Genetics Co.

Legal name

瑞寶基因股份有限公司

Website

https://reber.com.tw

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

51–100 employees

Short description

Reber Genetics Co., Ltd. is a Taiwanese PIC/S GMP-certified animal vaccine developer that commercializes proprietary targeted subunit vaccines — including the world's first PRRS and PED swine subunit vaccines — primarily for commercial pig farms across Taiwan and Asia.

Ownership category

akta.pro rank

Product category

Animal Vaccines / Veterinary Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB)

akta.pro secondary industries

Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM), Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO) (HLAMAKAI), Veterinary Vaccines (Biologics) (HLAMAEAL)

Keywords

• Animal vaccine development
• Subunit vaccine technology
• Swine disease prevention
• PIC/S GMP manufacturing
• Veterinary biopharmaceuticals

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Animal Vaccine Product Sales: Revenue from sale of proprietary animal vaccine products including PRRSFREE/PRRSQ, CIRCOQ, and PEDQ vaccines to pig farmers and distributors domestically and internationally.
2. Distribution Agent Sales: Revenue from acting as a domestic and international distribution agent for foreign vaccine products.
3. ODM/OEM Animal Vaccine Manufacturing: Custom animal vaccine design and contract manufacturing services for other animal health companies.
4. Technology Licensing and Patent Authorization: Technology transfer, patent licensing, and cooperation opportunities leveraging proprietary subunit vaccine platform.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Reber Genetics Co., Ltd. develops, manufactures, and sells targeted subunit animal vaccines for major swine diseases (PRRS, PCV2, PED, Classical Swine Fever) using a proprietary platform that combines detoxified Pseudomonas exotoxin A antigen delivery with reverse genetic engineering and target cell-specific fusion antigen technology. The company also offers ODM/OEM animal vaccine contract manufacturing, domestic and international distribution agency services for foreign animal health products, and technology licensing/patent authorization of its subunit vaccine platform.

Product overview

Reber Genetics Co. is a Taiwanese animal vaccine R&D and manufacturing company offering a portfolio of innovative subunit vaccines for swine diseases. The company's core technology platform combines reverse genetic engineering and targeted cell-specific fusion antigen technology to develop safe, effective subunit vaccines. The product portfolio includes: 康活™ (PRRSQ™) - world's first PRRS subunit vaccine; 圓滿™ (CIRCOQ™) - PCV2 subunit vaccine; 免痢™ (PEDQ™) - globally unique PED subunit vaccine; PCCOM™ - combined PCV2/PRRS vaccine; and HCFREE (安穩™) - CSF E2 vaccine. The company operates PIC/S GMP certified manufacturing facilities and focuses on applying human cancer immunotherapy techniques to animal disease treatment.

Differentiator

Problem solved

Functional benefit

Brands

• PRRSQ (寬活/PRRSFREE): World's first PRRS subunit vaccine targeting Porcine Reproductive and Respiratory Syndrome (PRRS, blue-ear disease). Features targeted antigen delivery platform using Pseudomonas exotoxin; induces both humoral and cell-mediated immunity.
• CIRCOQ (圓滿)
• PEDQ (免痢)

Products and services

• PRRSFREE (康活/PRRSQ) Porcine Reproductive and Respiratory Syndrome Subunit Vaccine World's first PRRS (Porcine Reproductive and Respiratory Syndrome / blue-ear disease) subunit vaccine using the proprietary Pseudomonas exotoxin A antigen delivery platform. Induces both humoral and cell-mediated immune responses, demonstrates safety without inducing negative immune suppression (Treg), helps pig herds establish efficient cellular immunity to clear PRRS virus, and does not induce viral mutation or reversion to virulent form. Significantly reduces sow abortion rates, stillbirths, and improves livability of newborn piglets. Sold in 50-dose vials. Valid period extended to 36 months.
• CIRCOQ (圓滿) Porcine Circovirus Type 2 Subunit Vaccine Targeted PCV2 (Porcine Circovirus Type 2) subunit vaccine precisely designed for Taiwan's predominant PCV2 2d genotype strain. Combines reverse genetic engineering and fusion protein platform to induce neutralizing antibodies and cellular immunity. Demonstrates significant improvement in pig uniformity and daily weight gain, helping pig farms shorten fattening cycles and accelerate market timing. Sold in 100-dose vials.
• PEDQ (免痢) Porcine Epidemic Diarrhea Subunit Vaccine Globally unique PED (Porcine Epidemic Diarrhea) subunit vaccine using the G2IIb new vaccine strain. Contains both inactivated whole-virus particles and spike protein subunit antigens. Through enhanced maternal antibody transfer, rapidly stabilizes farrowing room production lines during outbreak high-pressure periods, significantly controlling batch death losses and gradually improving herd diarrhea conditions. Protects suckling piglets via maternal antibody transfer.
• PCCOM Dual/Combined PCV2 + PRRS Subunit Vaccine Combined PCV2 and PRRS subunit mixed vaccine providing dual protection against both Porcine Circovirus Type 2 and Porcine Reproductive and Respiratory Syndrome in a single vaccination.
• HCFREE (安穩) Classical Swine Fever E2 Subunit Inactivated Vaccine Classical Swine Fever (CSF) E2 gene-engineered subunit inactivated vaccine targeting Classical Swine Fever virus. Applied for new drug registration in Taiwan in 2016.
• ODM/OEM Animal Vaccine Contract Manufacturing Services Custom animal vaccine design and contract manufacturing services provided to other animal health companies using Reber's PIC/S GMP-compliant Guanyin factory (Taoyuan) with 100M+ dose annual capacity.
• Technology Licensing and Patent Authorization Technology transfer, patent licensing, and cooperation opportunities leveraging Reber's proprietary targeted subunit vaccine platform (Pseudomonas exotoxin antigen delivery + reverse genetic engineering + fusion antigen technology), with patents granted in Europe, USA, China, South Korea, and Canada.
• Domestic and International Animal Vaccine Distribution Agency Services Reber Genetics acts as a distribution agent in Taiwan and selected international markets for foreign animal vaccine products, leveraging its established distributor network and regulatory expertise.

Quantifiable outcome

• Sow abortion rate reduced by 80% with PRRSQ vaccine
• +6 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

13 partnerships are on record, tiered minor and core.

• Reber Genetics (as distribution partner for KAICO in Taiwan)minorChannel Partner/ Reseller/ Distributor · 1 March 2026Reber Genetics established as distribution partner in Taiwan for KAICO's KAICO Powder pig feed additive product, expanding Reber's product portfolio beyond vaccines into feed additives. This represents Reber acting as a distributor for Kaico's product in Taiwan.
• Kaico Co., Ltd.coreStrategic or Co-development Partner · 1 November 2025Reber Genetics completed a technical exchange visit to Kaico's headquarters in Japan to explore the Silkworm Expression System (SES) for recombinant protein production. Discussions focused on using SES platform for high-efficiency, low-cost production of novel swine and avian vaccine antigen proteins, high-purity antibody production for diagnostic kits, and combining Reber's vaccine adjuvant expertise with Kaico's protein expression technology for next-generation animal health products. CTO Dr. Frank Chang stated this collaboration could be 'groundbreaking' especially for addressing emerging animal epidemics.
• Meiji Animal Health Co., Ltd.coreGTM or Marketing Partner · 1 November 2025Long-standing strategic business partnership in Japan and Asia-Pacific markets. At APVS 2025, both companies held adjacent booths (#23 and #1) and conducted in-depth business meetings to discuss promoting Reber's high-quality swine vaccine products to Japanese and Asia-Pacific pig farmers. Both companies aim to provide comprehensive disease prevention solutions through this partnership.
• P&Y Livestock Services Co., Ltd. (Vietnam)minorChannel Partner/ Reseller/ Distributor · 1 September 2025Vietnamese livestock services company that invited Reber's CTO to present at a PCV and Salmonella seminar and serves as a local agent for Reber's CIRCOQ vaccine promotion in Vietnam.
• National Pingtung University of Science and Technology (NPUST) - Professor Chu ChwiyancoreStrategic or Co-development Partner · 1 April 2025Collaborative research partnership for next-generation swine coronavirus vaccine development. Joint work won the 2024 Taiwan Innovation Technology Expo Future Tech Award. Also collaborated on PED vaccine development with Professor Chang Hui-wen of National Taiwan University.
• Taiwan Animal Health Research Institute (畜衛所)coreStrategic or Co-development Partner · 1 May 2020Signed MOU for cooperation in animal vaccine R&D and technology transfer, and acceleration of technology commercialization. The partnership aims to promote animal welfare and benefit farmers through joint development of animal vaccines.
• Agricultural Technology Research Institute (Taiwan)minorStrategic or Co-development Partner · 1 January 2008Collaborative research institution for vaccine development. Included in Reber's network of leading research institutions for technology supplementation.
• Development Center for Biotechnology (Taiwan)minorStrategic or Co-development Partner · 1 January 2008Collaborative research institution. Included in Reber's network of leading research institutions for technology supplementation.
• Industrial Technology Research Institute - Biomedical Center (Taiwan)minorStrategic or Co-development Partner · 1 January 2008Collaborative research institution for biotechnology development. Part of Reber's institutional research network.
• National Taiwan UniversityminorStrategic or Co-development Partner · 1 January 2008Academic partnership for vaccine research. Dr. Frank Chang earned PhD from National Yang-Ming University. Collaborated on PED vaccine development with NTU veterinary professor.
• Nong Lam University (Vietnam)minorStrategic or Co-development Partner · 1 January 2008Academic partnership in Vietnam for swine disease workshops and CIRCOQ vaccine field trials. Dean Dr. Đinh Xuân Phát provided interpretation assistance during presentations. Dr. Chia-Jung Chang invited to present at Vaccinology and Diagnostic Techniques in Swine Workshop.
• National Chiayi University, Fooyin UniversityminorStrategic or Co-development Partner · 1 January 2008Academic partnerships listed as part of Reber's research network.
• Johns Hopkins University (USA), Kansas University (USA)minorStrategic or Co-development Partner · 1 January 2008International academic partnerships listed as part of Reber's research network for vaccine development.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Regional players

• Qilu Animal Health Products: Chinese veterinary biologics manufacturer producing swine vaccines (PRRS, PCV2, PED) at scale for the domestic market. Comparable as a regionally dominant veterinary vaccine company targeting overlapping swine diseases.
• Ringpu (Jin Yu Biotechnology): Chinese veterinary vaccine company specializing in livestock (swine, poultry) vaccines. Comparable as a regional veterinary biologics company targeting similar swine disease profiles.
• China Animal Husbandry Industry Co. (CAHIC): Major Chinese state-affiliated animal vaccine manufacturer with dominant domestic share in swine vaccines. Most relevant peer for assessing Reber's competitive position in the pending China registration market.

Broad incumbents

• Merck Animal Health: Global animal-health division of Merck with broad livestock and companion-animal vaccine portfolio, including swine respiratory and reproductive vaccines. Comparable in targeting PRRS, PCV2, and PED through different technology platforms.
• Boehringer Ingelheim Animal Health: Global animal-health major and Reber's most direct competitor in the Taiwan PRRS vaccine market, which Reber displaced to capture 55% domestic share. Competes with PRRS, PCV2, and PED portfolios across Asia and globally.
• Ceva Santé Animale: Global animal-health company with strong swine vaccine portfolio, particularly in Asia and Europe. Competes with Reber in PRRS, PCV2, and reproductive disease management.
• Elanco Animal Health: Major animal-health player with swine and poultry vaccine offerings following the Bayer Animal Health acquisition. Competes in the same disease targets as Reber with broader species coverage.
• Zoetis: Largest pure-play animal-health company globally, offering vaccines across livestock and companion animals. Competes in swine vaccine portfolios and has the scale to challenge Reber in regulated Asian markets.

Direct peers

• HIPRA: Spanish veterinary biologics specialist focused on livestock and aquaculture vaccines, particularly swine. Comparable in being a mid-sized, technology-focused vaccine developer competing against larger incumbents.
• Phibro Animal Health: Animal-health company focused on livestock vaccines, health, and nutrition. Comparable in targeting swine and poultry health with proprietary biologics offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/ReberGenetics
• LinkedInlinkedin.com/company/reber-genetics-co.-ltd.

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Reber Genetics Co.